Unibest
← Back to patent-cliff list

Vilagletistat

Tier C — Watch / trade

Vilagletistat

Zedira GmbH
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:TGM2

Indications (approved):乳糜泻, Non-alcoholic steatohepatitis, Liver cirrhosis

Regional status

US
Phase I
2023-05-25
EU
Phase II
2022-04-19
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 11 · Total yield 1.42 g
ZED-1227—ZED-1227-0016332-56-5ZED-1227-002171559-74-3ZED-1227-003147283-78-1ZED-1227-004617-79-8ZED-1227-0051542133-32-3ZED-1227-0061542133-28-7ZED-1227-0071026102-79-3ZED-1227-0081542133-34-5ZED-1227-00924277-39-2ZED-1227-01024277-38-1ZED-1227-011226985-04-2ZED-1227-012129241-89-0ZED-1227-013761001-89-2API · Vilagletistat
CodeCAS No.Intermediate
ZED-1227--
ZED-1227-0016332-56-53-nitropyridin-2-ol
ZED-1227-002171559-74-3tert-butyl 2-(3-nitro-2-oxopyridin-1(2H)-yl)acetate
ZED-1227-003147283-78-12-(3-nitro-2-oxopyridin-1(2H)-yl)acetic acid
ZED-1227-004617-79-82-ethylbutan-1-amine
ZED-1227-0051542133-32-3N-(2-ethylbutyl)-2-(3-nitro-2-oxopyridin-1(2H)-yl)acetamide
ZED-1227-0061542133-28-72-(3-amino-2-oxopyridin-1(2H)-yl)-N-(2-ethylbutyl)acetamide
ZED-1227-0071026102-79-3(S,E)-2-((tert-butoxycarbonyl)amino)-7-methoxy-7-oxohept-5-enoic acid
ZED-1227-0081542133-34-5methyl (S,E)-6-((tert-butoxycarbonyl)amino)-7-((1-(2-((2-ethylbutyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-7-oxohept-2-enoate
ZED-1227-00924277-39-2(S)-5-(tert-butoxy)-4-((tert-butoxycarbonyl)amino)-5-oxopentanoic acid
ZED-1227-01024277-38-11-(tert-butyl) 5-methyl (tert-butoxycarbonyl)-L-glutamate
ZED-1227-011226985-04-2-
ZED-1227-012129241-89-0-
ZED-1227-013761001-89-2-

Frequently asked questions

What are the approved indications of Vilagletistat?

Approved indications include: 乳糜泻, Non-alcoholic steatohepatitis, Liver cirrhosis.

When does the Vilagletistat patent expire?

No public expiry year is available for Vilagletistat yet; this page updates once verified.

How many synthesis routes are recorded for Vilagletistat?

1 synthesis routes are recorded; the shortest is 11 steps with 1.42 g total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Vilagletistat intermediates?

All intermediates in Vilagletistat routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Vilagletistat intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-05